An oral drug from Pfizer causes a similar amount of weight loss as the blockbuster Ozempic injection, made by rival Novo Nordisk, according to results from a phase two clinical trial. The results were ...
Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once monthly injection. The company plans more than 20 anti-obesity trials, ...
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the ...
(RTTNews) - Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, ...
Pfizer’s Hympavzi receives European approval to treat adults and adolescents with haemophilia A or B with inhibitors: New York Thursday, May 14, 2026, 09:00 Hrs [IST] Pfizer Inc ...
NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results